Skip to main content

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 and FINCH 3 trials

John Isaacs comments on the findings from the FINCH 1 and FINCH 3 trials and discusses how filgotinib might fit into the rheumatoid arthritis treatment landscape (2:56).

Related topics

Have your say on Medicine Matters

Visit the conference hub

Image Credits